cancer in an animal model. METHODS: To measure the effects on tumour cell growth in vitro, IFN-b-producing MSCs (IFN-b-MSCs) were co-cultured with the prostate cancer cell line PC-3. The in vivo migration of intravenously injected fluorescentlylabelled MSCs to healthy tissues and PC-3 xenograft tumours grown in immunodeficient mice was determined by fluorescence microscopy. The antitumour effects of intravenously injected IFN-b-MSCs on PC-3 xenograft growth and animal survival were also investigated. RESULTS: IFN-b-MSCs inhibited the growth of PC-3 cells in vitro. Fluorescently-labelled MSCs migrated to the margins and centre of tumour masses but not into healthy tissues. Intravenously injected IFN-b-MSCs significantly reduced PC-3 xenograft tumour weight and increased animal survival compared with controls. CONCLUSIONS: Intravenously injected IFN-b-MSCs inhibited PC-3 xenograft growth. This could be an effective gene delivery system for treatment of solid human tumours.
Introduction
Despite the success of chemical or surgical castration in the treatment of prostate cancer, androgen independence and resistance to existing treatments is a common feature of metastatic disease. 1 There is currently no optimal treatment for decreasing disease progression in patients with metastatic disease. 2 Gene therapy is a potentially viable approach for treating advanced prostate cancer, but delivery problems have slowed the development of gene therapy strategies. 3 Mesenchymal stem cells (MSCs) are derived from bone marrow and have multiple differentiation potentials. Human bone marrow-derived stem cells are well suited for clinical application because they are easily obtained from bone marrow aspirates, can be expanded in vitro and their use avoids immunological incompatibilities. 4 Recent evidence suggests that stem cells are useful delivery vehicles for solid tumour therapy 5 -7 and they could, therefore, be applied to the treatment of metastatic prostate cancer. The present study explored the effects of MSCs genetically engineered to produce interferon-a G-X Wang and Y-A Zhan contributed equally to this article. IFN-b-producing mesenchymal stem cells as cancer gene therapy β (IFN-β) on the growth of the prostate cancer cell line PC-3 and investigated the feasibility of using MSCs as a gene vector to treat prostate cancer.
Materials and methods

CELL CULTURE
All protocols were performed according to the Scientific Research Ethical Committee at The First Affiliated Hospital of Nanchang University, Nanchang, China. Bone marrow was extracted from the iliac crest of healthy adult volunteers, who provided written informed consent and were given guarantees of confidentiality. Human MSCs were isolated from bone marrow and cultured as previously described. 8 Briefly, bone marrow was washed with Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, Grand Island, NY, USA) and marrow mononuclear cells were purified by Percoll ® density gradient centrifugation (1.073 g/ml; Sigma Aldrich, St Louis, MO, USA) at 1000 g for 20 min. Mononuclear cells were plated at a density of 1 × 10 6 cells/ml in DMEM supplemented with 10% fetal bovine serum (FBS; PAA Laboratories, Pasching, Austria) and incubated at 37°C with 95% humidity and 5% carbon dioxide. The human prostate cancer cell line PC-3 was purchased from the Chinese Centre for Type Culture Collection, Wuhan University, Wuhan, China. The PC-3 cells were maintained in DMEM containing 10% FBS and 1% penicillin/streptomycin (100 U/ml). Cells were seeded into culture flasks at a density of 1 × 10 6 cells/ml and maintained at 37°C with 95% humidity and 5% carbon dioxide.
ADENOVIRAL VECTORS AND TRANSDUCTION OF HUMAN MSCS
The sequence of human IFNB1 was obtained from GenBank (RefSeq NM_002176), and the excretory IFNB1 codon was employed to design the cDNA sequence (the gene segment was within the 76 -639 coding sequence). Gene synthesis and construction was completed by Welgen Inc. (Worcester, MA, USA). Human MSCs were transfected with the adenovirus AD 5 -IFN-β (Welgen Inc.). Fourth-passage MSCs were plated at a density of 1 × 10 5 cells per well in 12-well plates. After 24 h, the adenoviral vector was added at a multiplicity of infection of 2000 and incubated for 2 h. The cultures were then washed with 10 mM phosphatebuffered saline (PBS), pH 7.4, and the culture medium replaced. Parallel control cultures of MSCs (AD 5 -MSCs) were transfected with blank AD 5 virus vector (Welgen Inc.). Effective transfection was confirmed by IFN-β enzymelinked immunosorbent assay (ELISA) of the culture supernatant (Pestka Biomedical Laboratories Inc., Piscataway, NJ, USA) at 4, 24, 48, 72, 96 and 120 h after transfection. The transfection efficiency of AD 5 -IFN-β was determined by in situ immunofluorescence staining where cells were fixed in 4% cold paraformaldehyde at room temperature for 20 min, incubated with 0.2% Triton in 10 mM PBS (pH 7.4) for 10 min at room temperature and washed three times with PBS. Cells were incubated with rabbit antihuman IFN-β polyclonal antibody (1 : 100 dilution; PeproTech, Rocky Hill, NJ, USA) or PBS (as negative control) overnight at 4°C, washed three times with PBS and incubated with goat antirabbit fluorescein isothiocyanateconjugated immunoglobulin G (1 : 200 dilution; Southern Biotech Associates, Birmingham, AL, USA) for 1 h at 37°C. After washing three times with PBS, immunostaining was visualized using an Olympus 17X1 fluorescence microscope (Olympus, Tokyo, Japan) and DP Manager software, version 1.1.1.65 (Olympus). Each experiment was performed in triplicate and IFN-β immunostaining was scored as positive or negative. IFN-b-producing mesenchymal stem cells as cancer gene therapy
CO-CULTURE WITH IFN-b-MSCS
A 12-well Transwell ® culture system with polyester membrane and 0.4 µm pore size (Corning, Lowell, MA, USA) was employed for co-culture experiments with the prostate cancer cell line PC-3. The cells were plated into the lower chamber of the Transwell ® plate at a density of 5 × 10 5 cells/well and incubated for 48 h. MSCs were transfected with adenovirus vector, as described above, in the upper chamber of a separate Transwell ® culture system (without PC-3 cells). The transfected MSCs were washed twice with 10 mM PBS, pH 7.4, and immediately transferred into the plate containing PC-3 cells. Control cultures used unmodified MSCs, AD 5 -MSCs, or 1000 IU/ml human recombinant IFN-β (PeproTech) in the upper chamber of the Transwell ® plates. There were 12 samples in each group. The PC-3 cells were harvested after 3 or 5 days of co-culture, stained with 0.04% trypan blue solution, and counted using a haematocytometer and a light microscope. Mean data from triplicate experiments were used to generate growth curves.
MOUSE XENOGRAFT MODEL
Male mice (C.B-17/Icr, 20 -25 g, aged 8 weeks; 110 animals in total) with severe combined immune deficiency (SCID), were purchased from the Laboratory Animal Centre of Beijing, Beijing, China. The animals were housed two per cage in pathogen-free facilities in a 12 h light/12 h dark cycle with free access to food and water. Animal studies were performed in accordance with the guidelines of the Institutional Animal Care and Research Ethical Committee, Nanchang University, Nanchang, China. PC-3 cells were suspended at a density of 3 × 10 5 cells in 200 µl 10 mM PBS, pH 7.4, and injected subcutaneously into the right forelimb-pit of the SCID mice.
The seeding site was examined daily from day 3 after xenograft implantation to record solid tumour development.
HOMING OF MSCS TO TUMOUR TISSUE
The homing of MSCs to tumour tissue in vivo was determined by labelling the MSCs with the fluorescent dye 4′,6-diamidino-2phenylindole (DAPI; Biotium Inc., Hayward, CA, USA), as follows. Fourth-passage MSCs were incubated in culture medium containing DAPI (final concentration 50 µg/ml) overnight in the dark. The medium was discarded and the MSCs were washed a minimum of six times with 10 mM PBS, pH 7.4, to remove unbound DAPI. The MSCs were protected from light throughout the labelling process. DAPI-labelled MSCs were resuspended in PBS (2 × 10 5 cells/0.2 ml) and injected into the tail vein of SCID mice (four animals) bearing subcutaneous PC-3 tumours when the tumour had reached approximately 0.5 cm in diameter. The MSCs were injected twice at weekly intervals and the mice were killed by asphyxiation with carbon dioxide 17 days after the second injection of MSCs. Frozen sections of the PC-3 xenograft tumours and other healthy tissues including liver, lung, spleen, kidney and muscle were taken. Fresh tissue samples were embedded in Tissue-Tek ® OCT™ compound (Miles Laboratories Inc., Elkhart, IN, USA), snap-frozen in liquid nitrogen and stored at -80°C. Frozen tissue was cut into 3 -5 µm-thick sections, mounted onto slides and examined with an Olympus 17X1 fluorescence microscope.
In order to observe whether the MSCs in the PC-3 solid tumours were intact, four SCID mice were treated with intravenous injection of 2 × 10 6 chloromethyl-docarbocyanine (CM-DiI; CellTracker™ CM-DiI; Molecular Probes Inc., Eugene, OR, USA)-labelled MSCs IFN-b-producing mesenchymal stem cells as cancer gene therapy in 0.2 ml PBS. CM-DiI labelling was performed according to the manufacturer's instructions. The PC-3 tumours were excised 17 days after the injection and frozen sections were prepared as described above. Sections were then mounted onto glass slides, fixed with 5% formalin, permeabilized in -20°C methanol and stained with 0.3 µM DAPI at room temperature for 10 min, to label all nuclei. The labelled sections were then covered with Aqua Poly/Mount (Polysciences, Warrington, PA, USA) and viewed with fluorescence microscopy within 24 h of DAPI staining. The red CM-DiI fluoresence images were superimposed onto the DAPI-stained images.
EFFECT OF IFN-b-MSCS ON PC-3 TUMOUR WEIGHT
Subcutaneous tumours grew to approximately 0.5 cm in diameter 2 weeks after PC-3 tumour cell injection. Mice were divided into seven groups of six animals and treated with IFN-β-MSCs (2 × 10 6 cells/dose or 2 × 10 5 cells/dose), AD 5 -MSCs (2 × 10 6 cells/dose), unmodified MSCs (2 × 10 6 cells/dose), AD 5 -IFN-β (2 × 10 9 viral particles/dose) or recombinant IFN-β (100 000 IU/dose). The final group of animals was left untreated as a control. Cell and virus suspensions were injected intravenously three times in total for each group at weekly intervals. Recombinant IFN-β was injected subcutaneously every other day over the duration of the experiment. Mice were killed by asphyxiation with carbon dioxide 30 days after PC-3 cell implantation. Entire tumour weights were measured in all animals.
SURVIVAL ANALYSIS
Mice were divided into seven groups of six animals and treated as above. Cell and virus suspensions were injected intravenously five times in total at weekly intervals.
Recombinant
IFN-β was injected subcutaneously every other day until death. All mice were followed daily until death and the survival time was recorded.
STATISTICAL ANALYSES
Results of in vitro experiments were analysed using analysis of variance or Student's t-test. Differences in tumour weights between treatment groups were analysed with the Kruskal-Wallis test, and pairwise comparisons of the treatment effect on tumour weight between groups were performed using the Nemenyi test. Betweengroup differences in survival data were determined by log-rank test. Analyses were carried out using SPSS ® software package, version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . All statistical tests were two-sided and a P-value < 0.05 was considered statistically significant.
Results
The presence of transgenic IFN-β protein in the supernatant above the IFN-β-MSCs was confirmed by ELISA. The concentration of IFN-β peaked at 200 pg/ml 48 h after transfection (Fig. 1A) . Immunofluorescent staining indicated that human MSCs transfected with AD 5 -IFN-β produced IFN-β ( Fig. 1B) and AD 5 -MSCs did not (Fig. 1C) .
In a Transwell ® culture system, co-culture of PC-3 cells with IFN-β-MSCs significantly inhibited growth of the PC-3 cells compared with co-culture with AD 5 -MSCs or unmodified MSCs, recombinant IFN-β treatment, or PC-3 culture alone (P < 0.05 for each comparison; Fig. 2) .
The MSCs were distributed extensively in the PC-3 xenograft tumours ( Figs 3A, 3B ), but not in liver, lung, spleen, kidney or muscle. MSCs with a CM-DiI-positive membrane and DAPI-positive nuclei were located in the tumour tissue and remained IFN-b-producing mesenchymal stem cells as cancer gene therapy morphologically intact ( Figs 3C, 3D, 3E) .
Mice treated intravenously with either dose of IFN-β-MSCs cells had significantly smaller PC-3 xenograft tumours than the control group of untreated PC-3 xenografts (P < 0.05 for 2 × 10 6 cells/dose; P < 0.01 for 2 × 10 5 cells/dose; Fig. 4 ). In contrast, the mean weights of the tumour masses from mice treated with AD 5 -MSCs, unmodified MSCs, AD 5 -IFN-β virus or recombinant IFN-β were not significantly different from those of the untreated control mice (Fig. 4) . Systemically administered recombinant IFN-β did not significantly inhibit PC-3 xenograft tumour 
Discussion
Current treatments for most metastatic cancers have poor outcomes due to the excessive toxicity and short half-life of the therapeutic agent, and the inaccessibility of some of the tumour sites. 9 Cancer management by specifically targeted therapy is not only effective but it can also avoid damage to healthy tissues.
Therapeutic delivery systems have been developed that induce high levels of apoptosis in cancer tissue. 10 Systemic intravenous or intra-arterial administration of viral vectors has been limited by the neutralizing effects of antibodies and by immune-mediated organ toxicity, 11 and selective delivery of the therapeutic gene to widely disseminated metastatic sites has often proven to be unachievable. Insights into tumour immunology have lead to the concept of a tumour microenvironment, which is essential for the growth and development of the tumour. Increasing evidence suggests that inflammatory cells, vascular endothelial cells and fibroblasts in the tumour microenvironment are derived from bone marrow stem cells. 12 Bone marrow precursor cells injected into the circulation migrate predominantly to the tumour microenvironment and, subsequently, take part in formation of the tumour matrix. 13 -16 The current study found that MSCs, after injection into the tail vein of mice, migrated to the PC-3 xenograft tumour rather than to normal tissues (including lung, liver, spleen, kidney and muscle). The intravenously injected MSCs remained morphologically intact within the tumour tissue. MSCs have multiple differentiation potential within the tumour matrix. 17, 18 Local cell renewal is accelerated when local homeostasis is disrupted (by damage caused by injury, inflammation or tumours), requiring precursor/stem cells to repair the damage. MSCs migrate to lesions to form the matrix, where they can survive for > 1 year. 19, 20 Therapeutic strategies can, therefore, be developed that are based on the local production of tumouricidal biological agents by MSCs transduced to express specific genes of interest. MSCs have previously been shown to exert antitumour effects when transfected with adenoviruses expressing a variety of transgenes. 5 -7,15,21,22 The present study explored the therapeutic potential of MSCs as a delivery system into the tumour microenvironment, following their transduction with IFNB1. Human IFN-β is a potent antiangiogenic and antimetastatic molecule that can be used to inhibit the proliferation of multiple tumour cells. 23 -25 Intralesional delivery of IFNB1 results in the infiltration of tumour sites by large numbers of macrophages and 23 Immunohisto chemical studies have demonstrated that cell proliferation and the number of microvessels are reduced and apoptosis is increased in tumour tissue following IFNB1 gene transfer. 24,26 -28 Clinical trials have demonstrated, however, that the maximum tolerable dose of IFN-β is far less than the concentration required for an antitumour effect. 29, 30 The effective concentration cannot, therefore, be achieved in the tumour via intravenous injection of IFN-β. In addition, intratumour injection has many disadvantages, and multiple injections are unacceptable to patients. 31, 32 The present study demonstrated that human MSCs genetically engineered with IFNB1 were able to produce IFN-β. In vitro incubation of the prostate cancer cell line PC-3 with IFN-β-MSCs directly inhibited proliferation of human tumour cells. The present study also investigated whether human MSCs, like murine MSCs, 25 could inhibit the growth of human PC-3 xenograft tumours in mice. Importantly, IFN-β-MSCs that produced IFN-β locally in the tumour microenvironment inhibited malignant cell growth in vivo. There was no significant difference between the two doses of IFN-β-MSCs used (2 × 10 6 cells/dose versus 2 × 10 5 cells/dose) and both doses significantly prolonged survival in SCID mice. This study showed that recombinant IFN-β (1000 IU/ml), as well as IFN-β-MSCs, inhibited the growth of prostate cancer cells in vitro, but systemically administered recombinant IFN- β did not inhibit PC-3 xenograft growth in vivo. These findings are consistent with the known rapid metabolism and short half-life of IFN-β in the circulation, 30 and suggest that local continuous production of IFN-β by MSCs in the tumour microenvironment can overcome this limitation. Evidence that in situ injection of an adenoviral vector encoding for murine IFN-β into prostate tumours in nude mice inhibits tumour growth and metastasis in a dose-dependent manner has been published. 33 In contrast, however, the present study demonstrated that injection of AD 5 -IFN-β via the tail vein of mice had no impact on PC-3 xenograft tumour growth or survival.
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